OCUPHIRE PHARMA INC. - COMMON STOCK
1.2900
27-9月-24 14:59:54
15 分の遅延
株式
-0.0100
-0.77%
本日の幅
1.2502 - 1.3050
ISIN
N/A
ソース
NASDAQ
-
08 3 2022 07:00:02 提供 Nasdaq GlobeNewswire
-
08 2 2022 07:00:02 提供 Nasdaq GlobeNewswire
-
31 1 2022 05:00:00 提供 Nasdaq GlobeNewswire
-
Ocuphire to Host Virtual Investor R&D Day on January 31st
25 1 2022 06:00:01 提供 Nasdaq GlobeNewswire
-
08 12 2021 07:00:01 提供 Nasdaq GlobeNewswire
-
23 11 2021 08:00:01 提供 Nasdaq GlobeNewswire
-
Ocuphire Announces Financial Results for the Third Quarter 2021 and Provides Corporate Update
12 11 2021 06:00:02 提供 Nasdaq GlobeNewswire
-
01 11 2021 08:30:31 提供 Nasdaq GlobeNewswire
-
07 10 2021 06:00:01 提供 Nasdaq GlobeNewswire
-
01 10 2021 07:49:48 提供 Nasdaq GlobeNewswire
-
Ocuphire Pharma Presenting at Three Upcoming Healthcare Conferences This Fall
27 9 2021 06:00:00 提供 Nasdaq GlobeNewswire
-
Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03 9 2021 16:00:00 提供 Nasdaq GlobeNewswire
-
Ocuphire Pharma Presenting at Four Conferences in September
02 9 2021 06:00:02 提供 Nasdaq GlobeNewswire
-
Ocuphire Announces Financial Results for the Second Quarter 2021 and Provides Corporate Update
12 8 2021 06:00:01 提供 Nasdaq GlobeNewswire
-
Ocuphire Pharma Presenting at Two Conferences in August
06 8 2021 06:30:00 提供 Nasdaq GlobeNewswire
-
22 7 2021 07:00:02 提供 Nasdaq GlobeNewswire
-
Ocuphire Selected to Present at Multiple Ophthalmic Conferences in July
13 7 2021 08:00:01 提供 Nasdaq GlobeNewswire
-
Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
09 7 2021 16:00:00 提供 Nasdaq GlobeNewswire
-
Ocuphire’s VEGA-1 Phase 2 Trial in Presbyopia Meets Primary and Secondary Endpoints
30 6 2021 06:15:00 提供 Nasdaq GlobeNewswire